UNITED NATIONS/GENEVA: On Tuesday, the World Health Organization’s (WHO) technical advisory group requested “further clarifications” from Bharat Biotech for its COVID-19 vaccine Covaxin to undertake a final “risk-benefit assessment” for the vaccine’s Emergency Use Listing.
On November 3, the WHO technical advisory panel will meet again for a final review.
On April 19, Covaxin maker Bharat Biotech of Hyderabad submitted an EOI (Expression of Interest) to the WHO for the vaccine’s Emergency Use Listing (EUL).
On Tuesday, the technical advisory panel convened to analyse data on Covaxin in preparation for the emergency use listing.
“The TAG convened today (October 26, 2021) and determined that additional clarifications from the manufacturer are required before conducting a final EUL risk-benefit assessment for global use of the vaccine,” the WHO said, according to news agency PTI.
“The TAG expects to receive these explanations from the manufacturer by the end of this week and plans to reconvene on Wednesday, November 3 for the final risk–benefit evaluation,” WHO said.